Drug-Resistant Gonorrhoea in England: What the Latest Data Shows
Drug-resistant gonorrhoea is a growing public health concern in England. Surveillance data shows a rise in ceftriaxone-resistant and extensively drug-resistant infections, even as overall diagnoses fall. Accurate testing, the right antibiotic treatment, early diagnosis and follow-up care all help manage resistant strains, reduce transmission and protect the treatments that still work.
Gonorrhoea remains a common sexually transmitted infection (STI) in England, and growing resistance to antibiotics is making some cases harder to treat. Most infections still respond to treatment, but strains resistant to ceftriaxone, the main recommended antibiotic, have raised concern among public health experts.
The latest surveillance figures show that drug-resistant gonorrhoea remains relatively uncommon compared with total diagnoses, but services are detecting resistant cases more often. Understanding these trends, getting tested and accessing the right treatment all help protect your sexual health and limit further spread.
What Does the Latest Data Show About Gonorrhoea in England?
UK Health Security Agency (UKHSA) surveillance published on Gov.UK shows two clear trends: gonorrhoea diagnoses are falling but remain high, while cases resistant to key antibiotics keep rising.
In 2025, sexual health services in England recorded 63,943 gonorrhoea diagnoses, a 10.9% fall on the 71,766 recorded in 2024. However, fewer diagnoses do not ease the concern about antibiotic resistance.
According to UKHSA's provisional report published on Gov.UK, England had recorded 88 cases of ceftriaxone-resistant gonorrhoea by 31 August 2026. Of these, 25 were extensively drug-resistant, meaning they resisted both first-line and second-line treatments.
These figures show why surveillance matters. Resistant infections still make up a small share of overall diagnoses, but their growing number could make future treatment more challenging.
Latest surveillance finding | Reported figure |
Gonorrhoea diagnoses in England during 2024 | 71,766 |
Gonorrhoea diagnoses in England during 2025 | 63,943 |
Ceftriaxone-resistant cases reported by 31 August 2026 | 88 |
Extensively drug-resistant cases within that total | 25 |
What Is Drug-Resistant Gonorrhoea?
The bacterium Neisseria gonorrhoeae causes gonorrhoea. It can infect the genitals, rectum and throat, and it can lead to complications if left untreated.
Drug-resistant gonorrhoea develops when the bacteria change in ways that let them survive antibiotics that would normally kill them. Over time, the bacterium has become resistant to several types of antibiotics, leaving fewer reliable treatment options.
Why Is Antibiotic Resistance a Concern?
Antibiotics work by targeting bacteria, but genetic changes can allow some bacteria to survive. These bacteria may then multiply and spread.
Repeated exposure to antibiotics, inappropriate prescribing and the spread of resistant strains all add to the problem. That is why using the correct treatment and following clinical advice matter so much.
Which Antibiotics Are Affected?
Gonorrhoea has become resistant to several antibiotics once used to treat it. Resistance to ceftriaxone is particularly worrying because it remains the recommended first-line treatment in the UK.
Resistance to other medicines, including azithromycin and cefixime, also matters because clinicians may use these drugs in specific situations.
What Does Extensively Drug-Resistant Mean?
Extensively drug-resistant (XDR) gonorrhoea describes infections that resist both first-line and second-line treatments, as well as other antibiotics. These infections can be particularly hard to manage and may need specialist assessment and laboratory testing.
Is Gonorrhoea Becoming Antibiotic Resistant in England?
Yes. Surveillance shows that services are detecting antibiotic-resistant gonorrhoea more often in England, although most infections still respond to ceftriaxone.
UKHSA has reported a rise in ceftriaxone-resistant cases through 2024 and 2025. Most cases link back to travel to or from the Asia-Pacific region, where resistance is more widespread. Transmission within England remains limited, but close monitoring is essential because resistant strains can spread between sexual partners and communities.
How Does Resistance Spread?
Resistant bacteria can pass between people during sexual contact. Many people have no symptoms, so they can pass on an infection before anyone identifies it.
International travel can also bring resistant strains into England. Not everyone who travels will pick up a resistant infection, but travel helps explain why resistance surveillance matters.
What Do Gonorrhoea Cases in England Tell Us?
The number of gonorrhoea cases England records each year shows the wider burden of infection, while resistance testing shows how well existing antibiotics are likely to work.
These figures measure different things. A fall in total diagnoses does not mean antibiotic resistance is falling, so both trends need separate monitoring to guide prevention, testing and treatment.
How Is Drug-Resistant Gonorrhoea Treated?
Treatment depends on the type of resistance, the site of infection and your previous treatment history. Clinicians commonly treat gonorrhoea with ceftriaxone, usually given as an injection. However, resistant strains may not respond to standard antibiotics, which makes further testing important.
A laboratory culture shows which antibiotics are likely to work against the bacteria, so clinicians can choose a suitable treatment based on the results. If symptoms persist after treatment, further tests can check for antibiotic resistance, reinfection or another cause.
Why Testing Matters
Sexual health services use molecular tests to identify gonorrhoea. They may also take a culture to grow the bacteria and see which antibiotics are likely to work.
When clinicians suspect resistance, laboratory testing helps them choose the right treatment and supports public health surveillance.
What Happens If Treatment Fails?
If symptoms persist after treatment or a follow-up test shows the infection is still there, you need further assessment. Gonorrhoea treatment resistance is one possible explanation, alongside reinfection from an untreated partner or another underlying cause.
A healthcare professional may take more samples, arrange antibiotic susceptibility testing and seek specialist advice to find the most suitable treatment. Never use leftover antibiotics or change your medication without medical advice.
What Should You Do If You Think You Have Gonorrhoea?
Gonorrhoea can cause a yellow or green discharge, pain when urinating, pelvic discomfort, bleeding between periods or rectal symptoms. However, many people have no noticeable symptoms.
If you think you may have an infection, book a test at a sexual health clinic or another appropriate service. Avoid sex until a healthcare professional has assessed you and, if you test positive, until you have completed treatment and follow-up. Your partners may also need testing and treatment to reduce the risk of reinfection.
An online consultation with Fylde Clinic can help you understand your options and the right next step. Suspected gonorrhoea needs proper testing, and a possible resistant infection may need specialist sexual health care.
Conclusion
The latest data on gonorrhoea antibiotic resistance in the UK shows that resistant infections remain uncommon, but services are identifying them more often. Ceftriaxone still works for most infections, yet rising resistance makes accurate testing, appropriate prescribing and follow-up more important than ever.
Recognising symptoms, seeking timely testing and following professional advice can help reduce transmission and protect the effectiveness of available treatments. As surveillance continues, early diagnosis and responsible antibiotic use remain central to managing drug-resistant gonorrhoea in England.
Concerned about gonorrhoea or antibiotic resistance? Get clear, confidential online sexual health advice from Fylde Clinic on your testing options, treatment pathways and when to seek care.